Profiel
Julie B. Feder served as Vice President-Internal Audit at Genzyme Corp.
from 2008 to 2011.
Prior to that, she worked at Deloitte & Touche LLP from 1991 to 2008, where she held the position of Senior Manager-Audit, Consulting & Enterprise Risk.
In 2017, she briefly served as Chief Financial Officer at Verastem, Inc. From 2011 to 2017, she held the role of Chief Financial Officer at the Clinton Health Access Initiative.
Currently, she is the Chief Financial Officer at Aura Biosciences, Inc. since 2018.
Ms. Feder completed her undergraduate degree at Sy Syms School of Business.
Eerdere bekende functies van Julie Feder
| Bedrijven | Functie | Einde |
|---|---|---|
| AURA BIOSCIENCES, INC. | Financieel Directeur/CFO | 25-10-2024 |
| VERASTEM, INC. | Financieel Directeur/CFO | 01-06-2018 |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Financieel Directeur/CFO | 01-07-2017 |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Corporate Officer/Principal | 01-01-2008 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Comptroller/Controller/Auditor | - |
Opleiding van Julie Feder
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Aura Biosciences, Inc.
Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Commercial Services |
Verastem, Inc.
Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Commercial Services |
Sy Syms School of Business
Sy Syms School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















